Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Asad Haider is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/16/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | JNJ | Buy Now | Johnson & Johnson | $153.91 | 11.75% | Asad Haider 57% | $157 → $172 | Upgrade | Neutral → Buy | Get Alert |
| 04/08/2025 | LLY | Buy Now | Eli Lilly | $734.90 | 20.83% | Asad Haider 57% | $892 → $888 | Upgrade | Neutral → Buy | Get Alert |
| 04/08/2025 | ABBV | Buy Now | AbbVie | $171.75 | 12.95% | Asad Haider 57% | → $194 | Assumes | → Neutral | Get Alert |
| 04/08/2025 | PFE | Buy Now | Pfizer | $22.08 | 13.22% | Asad Haider 57% | $32 → $25 | Downgrade | Buy → Neutral | Get Alert |
| 04/08/2025 | BMY | Buy Now | Bristol-Myers Squibb | $49.39 | 11.36% | Asad Haider 57% | $67 → $55 | Downgrade | Buy → Neutral | Get Alert |
